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Monocytes are considered to be precursor cells of the mononuclear phagocytic system, 
and macrophages are one of the leading members of this cellular system. Macrophages 
play highly diverse roles in maintaining an organism’s integrity by either directly participating 
in pathogen elimination or repairing tissue under sterile inflammatory conditions. There 
are different subpopulations of macrophages and each one has its own characteristics 
and functions. In this review, we summarize present knowledge on the polarization of 
macrophages that allows the generation of subpopulations called classically activated 
macrophages or M1 and alternative activated macrophages or M2. Furthermore, there 
are macrophages that their origin and characterization still remain unclear but have been 
involved as main players in some human pathologies. Thus, we also review three other 
categories of macrophages: tumor-associated macrophages, CD169+ macrophages, and 
the recently named TCR+ macrophages. Based on the literature, we provide information 
on the molecular characterization of these macrophage subpopulations and their specific 
involvement in several human pathologies such as cancer, infectious diseases, obesity, and 
asthma. The refined characterization of the macrophage subpopulations can be useful in 
designing new strategies, supplementing those already established for the treatment of 
diseases using macrophages as a therapeutic target.
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introduction
The professional phagocytic cells have an efficient ability to ingest particles that have penetrated our 
innate immunity barriers. This function provides us protection against what would be potentially 
hazardous to health, whether origin pathogen or not. The monocytes are considered to be precursor 
cells of the mononuclear phagocytic system that comprises monocytes, macrophages, and dendritic 
cells (DCs). However, DC population may also originate directly from the DC precursor as revised 
by Collin et al. (1).
The existence of this cellular network as part of the immune system is required to remove microor-
ganisms through their phagocytic activity and the subsequent induction of immune responses mediated 
by T cells. But their presence is not only limited to counteracting pathogens with their antimicrobial 
activity but are also fundamental in repairing tissue under sterile inflammatory situations (2–4).
Thus, macrophage function is not limited to phagocytosis and degradation of pathogens, these 
cells are also able to discriminate self from non-self, aspect that emphasizes their importance in the 
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development of some tissue. For example, using a murine model 
carrying a loss-of-function in the gene encoding the transcription 
factor PU.1 (regulating myeloid protein expression), there was 
a reduction in the number of vessel intersection was observed 
leading to abnormal vasculature process and suggesting that 
macrophage contact with vessel junctions are required to promote 
vessel fusion (5, 6).
The current macrophage nomenclature is complex and some-
times leads to confusion due to versatile cells, and, as it will be 
discussed, macrophages possess functional plasticity mediated by 
microenvironment signals. In this review, we give an overview on 
the two main macrophage subsets, named according to stimuli 
inducing their polarization and cytokine profile that they deliver: 
(a) classically activated macrophages (M1 macrophages) and 
(b) alternatively activated macrophages (M2 macrophages). We 
included a discussion on three other subpopulations of monocyte-
derived macrophages: (c) tumor-associated macrophages (TAM), 
one subpopulation involved in cancer; (d) CD169+ macrophages; 
a subpopulation found in lymphoid organs and implicated in 
immune tolerance and antigen presentation; and (e) one mac-
rophage subpopulation, recently described as T cell receptor posi-
tive (TCR+) macrophages. Despite the limited information about 
CD169+ and TCR+ macrophages, we include them because there 
are accumulating data showing their role under specific conditions. 
We describe experimental evidence relative to phenotypic hetero-
geneity and effector functions and add a short description of the 
relationship between macrophage subsets and major pathologies 
where they have been involved.
Precursor Cell Origin of Macrophages
Monocytes, defined as circulating blood cells, are a population 
of mononuclear leukocytes, morphologically and phenotypically 
heterogeneous that constitute approximately 10% of peripheral 
blood cells in humans. In murine model, it was that blood mono-
cytes are produced by bone marrow (BM) from macrophage/
dendritic cell progenitor (MDP) cells. MDP lacks the ability to 
differentiate into granulocytic, megakaryocytic, lymphoid cells, 
and are considered as the direct precursor of monocytes from 
BM and consequently of blood monocytes (7, 8). It has been 
established that CCR2 and the chemokine chemoattractant 
protein 3 (MCP-3) are critical for BM monocyte mobilization and 
homeostasis maintenance (9). Under specific circumstances, the 
egress of monocytes from blood to inflamed tissue is dependent 
on both CCR2 and CX3 chemokine receptor 1 (CX3CR1) (10). 
However, it remains to be determined if these molecules are 
necessary for the migration of monocytes from BM to blood 
and finally to tissue, and, if they are also responsible for the 
recirculation of monocytes through the BM.
In 2003, Geissman et al. identified two populations of murine 
monocytes: a short-lived subset phenotypically described as 
Ly6C+CX3CR1loCCR2+CD62L+ and found in inflamed tissue, and 
a second subset with a longer half-life, phenotypically shown as 
Ly6CloCX3CR1hiCCR2−CD62L− and observed in non-inflamed 
tissues (11). These subsets of murine monocytes can be com-
pared with the two subpopulations of human monocytes already 
described nearly 30 years ago (12). Their main characteristics were 
related to different surface expression markers (CD14, CD16) 
and their distinct ability to deliver pro-inflammatory cytokines 
such as tumor necrosis factor alpha (TNF-α or TNF). Currently, 
these populations are called “classical” (CD14++CD16−) and 
non-classical (CD14+CD16++) monocyte subsets and these are 
synonymous of CD62L+ and CD62L− murine subsets, respectively 
(13, 14).
Hence, once monocytes are recruited from the BM to 
circulating blood, they can migrate to various tissues of the 
body and differentiate into macrophages and subsequently 
become macrophages with their own phenotypic and functional 
characteristics in a tissue-dependent manner. According to the 
specific anatomical site where they are recruited, they are dif-
ferently named as alveolar macrophages in the lungs, microglia 
in the central nervous system (CNS), and Kupffer cells in the 
liver (Figure  1). Recent literature has reviewed macrophage 
populations and considered the large diversity in phenotype and 
functions according to their anatomic localization. Italiani and 
Boraschi have recently reviewed human and murine monocyte 
subsets and the fate of monocyte/macrophage populations and 
functions in the main body tissues during steady state and inflam-
matory conditions (15). Dey et al. provided us an analysis about 
polarization, ontogeny, and plasticity of tissue macrophages inside 
a context of treatment of acute and chronic inflammatory diseases 
(15, 16). Finally, Gordon et al. have summarized the heterogeneity, 
functionality, and interactions of macrophage populations within 
body tissues (17).
In this review, we consider blood monocytes as tissue-
macrophage progenitors, because the major fraction of mac-
rophages originates from blood-borne monocytes. However, it 
is important to note that there are tissue-resident macrophages 
that are not derived from monocytes, and their self-renewal, 
proliferation, origin, and mechanisms of replacement have not 
been totally elucidated. In 1989, the presence of macrophages in 
the mouse yolk sac at day 9 of gestation was reported, suggesting 
that part of the macrophages may exist before promonocyte and 
monocyte development (18, 19). In the CNS, a murine model 
of microgliosis has illustrated that microglia can be function-
ally maintained independently of BM-derived progenitors 
(20). By contrast, there is also experimental evidence proving 
that microglia is derived from hematopoietic cells. Inhibition 
of monocyte recruitment to the CNS prevented experimental 
autoimmune encephalitis, suggesting that within the CNS, mac-
rophages can originate from both dependent and independent 
blood monocytes (21, 22). Recently, Davies et al. reported an 
extensive analysis confirming the co-existence of macrophages 
of dependent and independent blood monocyte-derived origin 
in several tissues including brain, spleen, and lung, and defined 
cellular phenotypes and functions of these tissue-resident 
macrophages (23). How the resident macrophage population 
is self-renewing is still an open question. Colony-stimulating 
factor 1 (CSF-1) was proposed as a protein necessary to regulate 
the number of tissue-resident macrophages (24); nevertheless, 
it has been shown that interleukin-4 (IL-4) plays a major role 
in favoring the local proliferation of macrophages in parasitic 
infections. Nevertheless, IL-4-mediated proliferation seems to 
be independent of CSF-1 (25, 26).
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Origin of M1 and M2 Macrophage 
Terminology
The concepts M1 and M2 oversimplify the pattern of macrophages 
because, as we will discuss, the combinatorial spectrum of these 
cellular populations is extremely large. The first classification of 
macrophages was adopted from the work on T helper cell polariza-
tion. Two main lymphocytic subpopulations were characterized 
with diametrically contrasting functions and categorized accord-
ing to patters of cytokines they deliver: T helper cells type 1 (TH1) 
and type 2 (TH2) (27).
From early 1980s, Nathan et  al. identified that interferon-
gamma (IFN-γ) stimulating the peroxide-releasing capacity of 
macrophages, contributes to macrophage ability to kill intracellular 
pathogens (28). Posteriorly, IL-4, an anti-inflammatory cytokine, 
was identified and shown to induce a different macrophage gene 
expression compared with IFN-γ dependent (29). However, it was 
only in 2000 when Mills et al. proposed the M1–M2 terminology. 
These authors used T lymphocytes from two mouse strains, one 
with a background producing mainly IFN-γ, which activates 
macrophages to generate nitric oxide (NO) from arginine versus 
FiGURe 1 | Monocytes are generated in the bone marrow and 
mobilized to blood and tissue through cytokine signaling to originate 
macrophage subsets. In the bone marrow, hematopoietic stem cells give 
rise to MDCP, which divides into two subsets of monocytes, Ly6C+CX3CR1lo 
CCR2+CD62L+ and Ly6CloCX3CR1hiCCR2−CD62L−. Both are mobilized to 
blood through CCR2 and MCP-3 signaling. Once inside the blood  
vessels, monocytes are able to leave by extravasation and arrive to  
tissues via CCR2 and CX3CR1 signaling. A macrophage will originate  
in a tissue-dependent manner and with its own characteristic and  
name.
mice which T lymphocytes producing IL-4 and TGF-β1, and 
generating ornithine from arginine. This elegant study showed 
that, in a strain-dependent manner, macrophages express distinct 
metabolic programs and their responses influence inflammatory 
reactions in opposite way (30).
Recently, Murray et al. proposed a nomenclature and experi-
mental guideline for generating in vitro M1 and M2 subpopula-
tions, with the objective to obtain data reproducibility across 
laboratories (31). In fact, the existence of this guideline notes the 
relevance to study M1/M2 paradigm as a useful network, which 
plays different roles inside immune responses.
Classically Activated Macrophages (M1 
Macrophages)
M1 macrophages are defined as macrophages that produce 
pro-inflammatory cytokines, mediate resistance to patho-
gens, and exhibit strong microbicidal properties, but these 
also contribute to tissue destruction. Classical activation 
of macrophages occurs when the cell receive stimuli such 
as: (1) IFN-γ, mainly secreted by other cell types (TH1 cells, 
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cytotoxic T cells, and NK cells); (2) lipopolysaccharide (LPS), 
a component of the outer membrane of Gram-negative bac-
teria; and (3) granulocyte-macrophage colony-stimulating 
factor (GM-CSF) that stimulates the production of pro-
inflammatory cytokines (32–34).
M1 macrophages are characterized by an elevated ability to 
secrete cytokines such as IL-1β, TNF, IL-12, and IL-18; pheno-
typically, they express high levels of main histocompatibility 
complex class II (MHC-II), CD68 marker, and CD80 and CD86 
costimulatory molecules. Recently, it has been shown that M1 
macrophages up-regulate the expression of intracellular protein 
called suppressor of cytokine signaling 3 (SOCS3), activate the 
inducible nitric oxide synthase (NOS2 or iNOS) generating NO. 
Hence, M1 macrophages, under specific conditions, exacerbate 
inflammatory processes that can be detrimental to health (35–37). 
However, these macrophages also have the ability to phagocyte 
large numbers of pathogens and can kill intracellular bacteria. 
When macrophages are under classical activation conditions, 
they initiate microbicidal mechanisms by the synthesis of NO, the 
restriction of iron or nutrients for microorganisms and acidifica-
tion of the phagosome (38–40).
At present, the pathway that regulates the macrophage 
polarization is not fully understood, but there are several mol-
ecules implicated in this process. For instance, members of the 
family of interferon regulatory factor (IRF), signal transducers and 
activators of transcription (STAT), and SOCSs. In 1990s, STAT1, 
a 91-kDa cytoplasmic protein, was shown to be crucial for M1 
macrophage polarization (41, 42). STAT1 can form homodimers or 
heterodimers (STAT1–STAT2) that bind to interferon-stimulated 
response elements (ISREs) and members of the IRF can also bind 
to ISRE sequences. In 2011, Krausgruber et al. showed that IRF5 is 
a critical protein for M1 macrophage polarization. Both GM-CSF 
and IFN-γ stimuli induce IRF5 expression that directly activate 
20 M1-specific genes and inhibit 19 M2-specific genes encoding 
cytokines (43).
Lipopolysaccharide stimulus generates M1 macrophages 
through interaction with its receptor, TLR-4, by inducing 
phosphorylation of both STAT1α and STAT1β. This pathway 
is MyD88-independent but is toll/IL-1R motif-dependent (44). 
A contribution from Bruton’s tyrosine kinase (Btk) is possible 
at this level since Btk is required downstream of TLR-4 for 
optimal phosphorylation of STAT1, and its absence exacerbates 
M2 recruitment under allergic inflammation conditions (45). 
Recently, Eun et al. showed that the P2Y(2) receptor (P2Y(2)R), a 
G-protein-coupled receptor, is up-regulated in response to LPS and 
facilitates the release of ATP, thus, P2Y(2)R increases NOS2–NO 
levels, which is a signature of M1 polarization (46). Arnold et al. 
reported experimental evidence supporting the hypothesis that 
up-regulation of SOCS3 is essential for an effective M1 macrophage 
activation. Indeed, SOCS3 controls activation and translocation 
of nuclear factor-κB (NF-κB) and activity of phosphatidylinositol 
3-kinase (PI3K), favoring NO production (37).
Finally, it has been shown that in an autocrine or paracrine 
manner, Activin A, a growth and differentiation factor of the 
TGF-β superfamily, promotes the expression of M1 markers and 
down-regulates the production of IL-10 probably leading to M1 
polarization (47, 48).
Autoimmune Diseases-Related M1 
Macrophages
Autoimmune diseases are frequently associated with inflammatory 
processes. Here, we briefly describe experimental evidence show-
ing a relationship between molecules previously described that 
support M1 polarization and the pathophysiology of autoimmune 
diseases.
The inflammatory bowel disease (IBD) is characterized 
by a chronic recurrent inflammation of the gastrointestinal 
tract. In both, murine model and biopsies of IBD patients, 
increase of SOCS3 expression has been observed, which was 
correlated with the severity of inflammation. Furthermore, 
SOCS3 expression has been proposed as a useful marker for 
cells undergoing acute or chronic inflammation (49–52). In 
systemic lupus erythematosus (SLE), an autoimmune illness 
characterized by chronic inflammation, patients displayed 
elevated levels of IFN-γ and IRF-5 (53). In addition, a risk 
haplotype of IRF5 has been described in SLE patients associated 
with the presence of anti-double-stranded DNA antibodies, 
which preceded clinical symptoms in many individuals (54). 
In addition, there is evidence that the SLE risk haplotype also 
influences systemic sclerosis predisposition, which is a fibrotic 
autoimmune diseases (55).
Multiple sclerosis (MS) is a demyelinating disease of the CNS. 
The role of macrophages in the CNS appears dual. Initially, it 
was shown that activated monocytes/macrophages could play a 
role in the acute exacerbation of MS in patients (56). However, 
experimental evidence suggested that GM-CSF (M1 inductor) 
was necessary to induce axonal regeneration (57). Using the 
experimental autoimmune encephalomyelitis (EAE) murine 
model, it has been reported that macrophages producing NO 
played an active role in the inflammation pathogenesis (58, 59). 
Experimental approaches attempt to reduce CNS inflammation 
using clodronate liposomes to eliminate infiltrating macrophages 
as well as G-protein-coupled receptor (GPBAR1), agonist to 
reduce pro-inflammatory cytokines; mice treated with clodronate 
liposomes or GPBAR1 agonist exhibited a significant decrease in 
EAE clinical score (60, 61).
Rheumatoid arthritis (RA) is an autoimmune disease character-
ized by a chronic inflammation of the synovial membrane that leads 
to joint destruction. Macrophage number has been correlated with 
disease activity in RA patients (62). Specifically, it has been shown 
that STAT1 is a signature in RA synovial fluid macrophages and 
dependent on autocrine TNF (63). At date, an effective treatment 
is proposed to block members of Janus kinase (JAK) family, JAK1 
and JAK3, since these molecules are necessary to phosphorylated 
STATs modulating gene expression toward M1 profile (64).
Type 1 diabetes mellitus is an autoimmune disease characterized 
by depletion of insulin-producing pancreatic beta cells (β-cells) 
and consequently, high levels of glucose. Under hyperglycemic 
condition, the generation of reactive oxygen intermediates and 
apoptosis by IFN-γ/STAT1-dependent pathway is increased (65, 
66). In murine model, it has been shown that β-cells increase 
the expression of CCL2 and allow pro-inflammatory monocyte 
recruitment in the pancreas and spontaneous development of 
diabetes (67). It has also been shown that macrophages from 
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diabetic mice have elevated expression of anti-apoptotic proteins 
as a potential mechanism to promote an attack toward β-cells (68).
Obesity-Related M1 Macrophages
Obesity has been implicated as the major risk factor in developing 
diverse diseases such as type 2 diabetes mellitus (69). Below, we dis-
cuss diverse evidence showing that obesity has a pro-inflammatory 
background. Although on a cellular level still remains largely 
unknown; however, it has been described, both in vitro and in vivo, 
that human adipocytes up-regulate of NF-κB-regulated genes, such 
as CCL2, E-selectin, IL-6, and IL-8, favoring the recruitment of 
macrophages (70, 71).
Weisberg et  al. showed that macrophage numbers were 
increased in adipose tissue in both mice and obese humans; their 
percentage correlated positively with their level of obesity, and 
these cells were responsible for almost all of the TNF and iNOS 
present in adipose tissue (72). Macrophages isolated from white 
adipose tissue from lean animals showed hallmarks of polarization 
toward an alternative activation state. By contrast, obesity induced 
increasing gene expression of molecules characteristic of M1 mac-
rophages, such as those encoding TNF and NOS2, suggesting that 
diet-induced obesity leads to a change from M2 to M1 polarization 
(72, 73). Animal models have shown that a high-fat diet increases 
systemic and tissue pro-inflammatory cytokines such as bioactive 
TNF, IL-6, and IL-12, reinforcing the hypothesis that obesity favors 
a pro-inflammatory microenvironment (74). In agreement with 
these data, Kawanishi et al. reported that physical activity mark-
edly inhibited TNF and increased CD163 (a M2 marker) mRNA 
expression in adipose tissue. Thus, it appears likely that exercise 
might induce the phenotypic switching from M1 macrophages to 
M2 macrophages in high-fat-diet animals (75).
infectious Diseases-Related M1 
Macrophages
Pro-inflammatory macrophages are necessary in controlling 
infectious processes, principally intracellular pathogens such 
as Mycobacterium tuberculosis (M. tuberculosis) or Listeria 
monocytogenes (L. monocytogenes), causal agents of tuberculosis 
and listeriosis, respectively. The array of pro-inflammatory and 
chemoattractant cytokines induced by M. tuberculosis infection 
play a significant role in cell recruitment, granuloma formation 
and progression, and severity of the disease (76). However, the 
inductions of pro-inflammatory cytokines and microbicidal mac-
rophage functions are necessary to activate protective host immune 
responses against mycobacterial infections (77, 78). It has also been 
proposed in murine model that during the later stages of infection 
the presence of alternatively active macrophages are increased, 
impairing NO production, and consequently favoring the intracel-
lular persistence of mycobacteria (79). Leemans et al. reported that 
macrophages play a dual role during tuberculosis since depletion 
of non-selective macrophage populations improved the clinical 
outcome, while depletion of activated macrophages enhanced 
mycobacterial outgrowth and decreased granuloma number, 
which is associated with a deficiency of TNF production (80). 
Mycobacterial proteins suppress functions of M1 macrophages 
as a mechanism of pathogen evasion. For instance, macrophages 
infected with a mycobacterial deficient strain of SecA2 produced 
high levels of TNF, IL-6, and reactive nitrogen intermediate (81), 
but the PE-PGRS62 protein supported virulence through down-
regulating IL-1β and iNOS mRNA levels (82, 83). These data, 
therefore, indicate that for the adequate control of M. tuberculosis 
infection, the development of a bactericidal mechanism of M1 
macrophages is required.
Listeria monocytogenes is a foodborne bacteria infecting a 
majority of organs including liver in which induces recruitment 
of pro-inflammatory monocytes and formation of micro-abscesses 
containing among other cells M1 monocyte-derived macrophages. 
Several chemokines have been shown to play a critical role in 
monocyte recruitment and infection control such as MCP-1 (also 
referred as CCL2, the ligand of CCR2), and MCP-3 (84). Mice 
deficient in CCR2 were unable to clear L. monocytogenes infection 
(85–87). The Notch signaling regulates diverse cellular process 
and after ligation with its ligand, it is cleaved, translocated to the 
nucleus, and binds to the DNA-binding protein RBP-J (88). Notch-
RBP-J and TLR-4 pathways synergistically induce expression of 
IRF8 protein that plays a role in activation of M1 macrophage 
polarization, autophagy, and clearance of L. monocytogenes (89, 
90). An interesting study by Bleriot et al. has shown that during of L. 
monocytogenes infection, necroptosis of Kupffer cells delivers IL-1β 
activating hepatocytes to produce the alarmin IL-33 triggering 
the basophil to produce IL-4 and resulting in a shift of M1 to M2 
macrophage phenotype. These M2 macrophages can replace dead 
Kupffer cells allowing attenuation of the inflammatory process and 
return to liver homeostasis. This study illustrates that sequential 
type 1 and type 2 immune responses after L. monocytogenes infec-
tion enable first host defense and then homeostasis (91).
Alternatively Activated Macrophages (M2 
Macrophages)
Macrophages activated through a pathway opposite to the classical 
pathway are referred to as M2 or alternative pathway. It has been 
demonstrated that stimuli such as CSF-1, IL-4, IL-10, TGF-β, and 
IL-13, fungi and helminth infections, favor M2 subpopulation 
polarization, delivering IL-10 in high concentrations, and IL-12 
in low amounts. M2 macrophages play a central role in responses 
to parasites, tissue remodeling, angiogenesis, and allergic diseases 
(25, 92).
Phenotypically, this population is characterized by the expres-
sion of the macrophage mannose receptor (MMR), also called 
CD206. However, in 2013 Jaguin et  al. observed no difference 
in CD206 expression between M1 and M2 macrophages and 
proposed that specific characteristic of M2 macrophages is the 
up-regulation of the CD200R membrane glycoprotein (93). 
CD163 has been suggested as M2 marker, but more recently was 
shown, in human tissue, that CD163 is M2 macrophage marker 
only in combination with the transcription factor CMAF, thus 
CD163 cannot be considered a M2 marker when used as unique 
marker (94). MGL1 and MGL2, two members of the macrophage 
galactose-type C-type lectin family, are also expressed in mac-
rophages stimulated upon conditions of alternative activation (95). 
Response gene to complement 32 (RGC-32) is a cell cycle regulator 
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expressed in many cells including macrophages but not monocytes 
(96). Recently, it has been shown that absence of RGC-32 does 
not affect monocyte-macrophage differentiation, however, under 
M-CSF or IL-4 stimuli, RGC-32 has a relevant role to promote 
M2 polarization and its level of expression still increases M2 
macrophages, proposing this protein to be included as a marker 
for M2 polarization (97).
Using a murine model, a genetic profile for M2 macrophages 
has been reported, and among other genes, arginase 1 (Arg1), 
MMR (Mrc1), resistin-like molecule α (FIZZ1), and chitinase-like 
protein Ym1 were shown to be up-regulated (98). In conclusion, 
to make an adequate phenotypic characterization of macrophage 
subpopulations, it is important to consider all described markers 
rather than individual markers, considering that some molecules 
can be shared by distinct cellular subsets.
The molecular network activated to favor M2 polarization 
involves distinct members of families already discussed to par-
ticipate in M1 polarization. On the one hand, Ohmori et al. showed 
that IL-4 is antagonistic to IFN-γ because it can suppress IFN-γ-
stimulated gene transcription and increase the activation of STAT6 
(99). Arginase 1 production, a hallmark of M2 macrophages, 
depends on IL-4 and IL-13, and is a direct consequence of STAT6 
activation (100). It has been shown that the NFκB p50 subunit, in 
the form of homodimers, has a regulatory activity essential for M2 
polarization, both in vitro and in vivo (101). IRF4, a member of IRF 
family, is involved in M2 polarization and functions as a negative 
regulator of TLR signaling by association with the MyD88 adap-
tor molecule (102). Peroxisome proliferator-activated receptor γ 
(PPARγ), a nuclear receptor with anti-inflammatory properties, 
has been proposed to enhance the M2 phenotype; however, only 
native monocytes can be primed by PPARγ, but not M2 resting or 
M1 macrophages (103). The treatment of human monocytes with 
bone morphogenetic protein-7 (BMP-7) induces M2 polarization 
and appears to be mediated by the p-PI3K–Akt–mTOR complex 
(104). On the other hand, it has been proposed that IL-21 can affect 
M2 polarization by inhibiting ERK phosphorylation and decreas-
ing iNOS, thus consequently increasing STAT3 phosphorylation 
(105). The detailed molecular network controlling M2 polarization 
still appears to be complex and is not fully understood.
M2 Macrophages in Allergy and Asthma
Allergic asthma is an inflammatory disease of the airway character-
ized by an increased reactivity to different allergens, and by TH2 
immune responses expressing IL-4, IL-5, and IL-13, as recently 
revised by Lambrecht and Hammad (106). Some clinical hall-
marks of asthma include increased IgE, eosinophilia, and airway 
hyperresponsiveness (AHR) (107). At the protein level, asthma 
pathology is known to depend on IL-4/IL-13 acting through IL-4 
receptor-alpha chain (IL-4Rα) and activating the STAT6 pathway 
(108). At present, exactly how M2 macrophages contribute to this 
pathology is not completely clear. Evidence using ovalbumin and 
house dust mites to induce an allergic airway disease in IL-4Rα 
KO mice, showed a decrease in macrophage Arginase1+ and 
Ym-1+ but the clinical pathological features were not reduced. 
By contrast, the presence of YM1-1+ macrophages responding 
to IL-4/IL-13 increased the severity of allergic lug inflammation 
as a consequence of M2 macrophage production of CCL11 and 
CCL24, two important mediators of eosinophil chemotaxis (109, 
110). Thus, it is possible that the discrepancy regarding the role 
of M2 macrophages in asthma physiopathology depends on dif-
ferent factors including the nature of the stimulus and the time 
of exposure.
M2 Macrophages in Helminth Parasite 
infection
Helminths have subversive immune strategies that allow them to 
evade the host’s immune response and to establish persistent infec-
tions. In 1998, Barner et al. showed that IL-4Rα-deficient mice were 
extremely susceptible to helminth infections suggesting that TH2 
responses regulate this type of infection (111). M2 macrophages 
are necessary for an adequate immune response against parasites; 
however, the exact mechanism through which M2 macrophages act 
has not been fully elucidated. It has been proposed that M2 mac-
rophages are an effector cell population impairing parasite health 
and mobility through the arginase 1 pathway and contributing to 
expulsion of adult worms (112). Using a model of the Strongyloides 
stercoralis infection, it has been reported that M2 macrophages can 
kill the parasites but this function depends on the collaboration 
between neutrophils and the complement system (113). Finally, 
the role of M2 macrophages during nematode infection has been 
considered to be not only limited to the elimination of the parasite 
but rather the TH2-type response is essential for controlling acute 
tissue damage and repair, which is their traditional role (114).
Tumor-Associated Macrophages
In a strict sense, TAM are not always considered as an additional 
subset of macrophages because these cells do not exist at steady-
state condition but are observed in many tumors. TAM are mac-
rophages associated with a specific pathological context and their 
specific polarization status has been the object of extensive studies 
supporting TAM as M2-like macrophages. However, there are also 
experimental evidence not only proposing TAM as one unique and 
distinct M2 myeloid population but also sharing M1 and M2 sig-
nature polarization (115–117). Switch of M2 macrophages toward 
M1 phenotype has been proposed as a therapeutic approach (118).
The microenvironment of solid tumors, releasing many chem-
oattractants, has the ability to induce recruitment of circulating 
monocytes, which may differentiate into TAM and are frequently 
found in tumors forming the main inflammatory infiltrate. It has 
been proposed that TAM can induce angiogenesis, lymphogenesis, 
stroma remodeling, immune suppression, and metastasis. TAM 
release different enzymes comprising plasmin, uPA, MMP, and 
cathepsin B contributing to tumor cell invasiveness and metastasis 
(119, 120). These cells accumulate in tumors mainly in necrotic 
regions, and are associated with a poor prognosis (121, 122).
Even if some features of TAM resemble M2 polarization, 
such as high production of IL-10, the same cells co-express 
IFN-inducible chemokines; this duality was recently described 
in freshly isolated TAM from pancreatic ductal adenocarcinoma. 
Cells exhibited anti- as well as pro-inflammatory properties 
supporting the idea that macrophages are main players of the 
TABLe 1 | Molecules involved in the polarization of M1, M2, and TAM 
macrophages.
M1 M2 TAM
iNOS production ↑ − +
MHC-II expression ↑ ↓ ↓
CD163 expression − + +










Arginase 1 − ↑ +
Cytokine production IL-18, IL-12, 
IL-1, TNF
IL-10, IL-12(low) IL-10, TGF-β, 
CCL2, CCL5
STAT molecules STAT1, STAT2 STAT3, STAT6 STAT1
IRF molecules IRF5 IRF4 ↑IRF3
NFκB participation p65 p50 p50
PI3K participation + + +
Genes Nos2, Ciita, ll12 Arg1, Ym1, ll10, 
Mcr1, Fizz1
Ccl2, Ccl5, ll10, 
CD81, H2Eb
“+” Present. “−” Ausent. ↑ High expression or production. ↓Low expression or 
production.
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epithelial–mesenchymal-transition favoring tumor formation 
and metastasis (123).
Although TAM show a pattern of M1 and M2 macrophages, it is 
known that these cells have a transcriptional profile distinct from 
M1 or M2 macrophages. Considering that there is an “overlap” 
of molecules between M1/M2/TAM, Table 1 summarizes some 
of the discrete differences that have been reported on molecules 
considered as specify marker for every one of these three types 
of macrophages.
As yet, it is not completely clear how the cascade of events 
generating TAM is orchestrated. Resting TAM are characterized by 
high expression of CCL2, CCL5, and IL-10 and surface molecular 
markers such as MGL1, Dectin-1, CD81, MHC-II, and scavenger 
receptor A (121, 124). It has been described that TAM activa-
tion pathway enhances IRF3, STAT1, and the release of CCL2, 
CCL3, CCL5, IL-10, IL-12 (low), as well as other molecules such 
as PGE2 and epidermal growth factor (124, 125). In a model of 
TAM derived from murine and human tumors, it has been shown 
that LPS activation of TAM resulted in defective NF-κB activation 
as well as inhibition of IL-12p40 promoter transcriptional activity. 
However, when TAM were cultured in standard conditions (out-
side the tumor microenvironment), they recovered the capacity 
to express IL-12 and TNF (126). These data suggest that tumor 
environment induces TAM to maintain a status of tolerance and 
consequently this may attenuate macrophage cytokine responses.
There is no precise information on how a monocyte precursor 
can generate the coexistance of both M1 and M2 markers in the 
same TAM. Regarding this question, Movahedi et  al. reported 
that the tumor-infiltrating monocyte pool were predominantly 
Ly6C+CX3CR1lo and suggested that Ly6Chigh monocytes were direct 
precursors of TAM. Then, they subdivided TAM in two groups 
according to intensity of MHC-II expression and suppression of 
T cell proliferation: (1) MHC-IIhi TAM suppressing proliferation 
using an iNOS-pathway and (2) MHC-IIlow TAM suppressing 
proliferation in an iNOS-independent pathway (127). Recently, 
Franklin et  al. reported experimental evidence supporting the 
idea that inflammatory monocytes could differentiate into TAM; 
as a late differentiation event, the integrin receptor VCAM1 was 
up-regulated, but terminal differentiation was dependent on the 
transcriptional regulator of Notch signaling, RBPJ (128). Laoui 
et al. have reviewed TAM subsets in breast cancer defining markers 
and functions (129).
It is important to note that, as previously discussed, STAT3 is 
involved in M2 macrophage differentiation; however, in addition, 
STAT3 also participates in TAM functions. STAT3 is required 
for expression of DC-SIGN on macrophages that might help 
tumor progression because these cells releasing IL-10 favor the 
maintenance of an activated STAT3 in a tumor context (130). In 
a hepatocellular carcinoma (HCC) model, it was shown that TAM 
secrete IL-6 activating STAT3 in HCC cells and promoting expan-
sion of cancer stem cells. This group proposed that targeting IL6/
STAT3 to inhibit cancer stem cell function has important therapy 
implications for the treatment of HCC (131). More recently, using 
the HCC model, a study identified that TAM produced high levels 
of IL-8, chemokine that induced epithelial–mesenchymal transi-
tion and promoted cellular migration by JAK2/STAT3 signaling 
pathway (132). Thus, these data indicate that STAT3 has a relevant 
participation in tumor progression, and could be considered as 
target molecule for anticancer therapy.
Mycobacterium bovis bacillus Calmette–Guerin (BCG) has been 
used for the immunotherapy of bladder carcinoma for more than 
30 years. It is clearly established that experimental BCG infections 
in murine model and in human vaccination induce a Th1 type 
immune response with activation of IFN-γ and TNF (77). Two 
strains of BCG, which are currently used for bladder carcinoma 
immunotherapy, were recently compared and the results showed 
that BCG Connaught strain provided better clinical outcome and 
better patient survival. In the same study, comparison of the two 
BCG strains in a murine model of bladder carcinoma demon-
strated that BCG Connaught strain-induced stronger Th1 immune 
responses suggesting that better BCG efficacy is associated to the 
activation of Th1 type immunity (133). Attempts to associate BCG 
treatment with TAM and M1 and M2 are in progress. The efficacy 
of BCG instillation in non-muscle invasive bladder carcinoma was 
associated with decrease M2, suggesting that M2 tumor infiltration 
can be considered as a marker for recurrence of tumors (134). 
Clinical trial using sequential combination of BCG and mitomycin 
with the objective to improve bladder cancer immunotherapy and 
to increase M1 TAM are in development (135).
CD169+ Macrophages
The antigen CD169, or Siglec-1, was originally reported as 
a marker of one macrophage subpopulation isolated from 
BM, lymph node, liver, and spleen (136). These cells had 
the ability to bind red cells. The CD169 molecule is highly 
expressed by macrophages found within the subcapsular 
sinus (SCS) and the medulla (M) of lymph nodes (LN) and 
marginal-zone (MZ) in spleen. So far, there is not sufficient 
information regarding the signaling pathway and activa-
tion of CD169+ macrophages as defined for M1 and M2 
macrophages (136, 137).
FiGURe 2 | Structure of spleen and lymph node. The spleen has 
two mayor components, white pulp that includes a central arteriole, T 
and B cells, and red pulp. Between red and white zone, there is a 
marginal zone where there are CD169+ macrophages (A). A lymph 
node is surrounded by a capsule, and the parenchyma is divided into 
cortex and medulla. The cortex has two zones: outer and inner zone. 
The subcapsular sinus and medulla zone contain CD169+ 
macrophages (B).
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The spleen has crucial roles in our body as filtering the blood, 
erythropoiesis, and is the largest secondary lymphoid organ. This 
organ is structured in compartments, comprising the white pulp 
that consists of a central arteriole and the T and B cell areas (splenic 
nodule), the red pulp surrounds the white pulp, and both pulps 
interact at the MZ (Figure 2A). From 1986, it was described that 
the murine MZ contains marginal metallophilic cells that are 
CD169+ and also promote adaptive immune response (138, 139).
Lymph nodes are secondary lymphoid organs integrated into the 
lymphatic system, whose main activities include filtering the lymph, 
maintaining and producing B cells, and detection of lymph-borne 
antigens. A LN is surrounded by a capsule, which is underlined 
with lymphatic endothelial cells forming the SCS. The parenchyma 
is divided into cortex, which has two zones: the outer cortex (B 
cell-rich) and the inner cortex (CD4+ T cell-rich), and the medulla 
(Figure 2B) (140). Thus, CD169+ macrophages are localized inside 
the SCS and M and their phenotype characterization remains 
ambiguous. In murine model, it has been clearly described some 
molecules as part of CD169+ macrophages characterization, the 
molecules included are CD11b, MHC-II, CD68, CD11c, and F4/80. 
However, F4/80 is expressed only on some CD169+ macrophage 
subpopulations. It has been proposed that inside of SCS there are 
CD169+ macrophages that are F4/80− while macrophages from 
the M are F4/80+. Finally, SCS macrophages, as splenic CD169+ 
macrophages, require lymphotoxin alpha (LT-α) signaling and can 
be depleted using clodronate liposomes (141, 142).
Recently, it was reported that CD169+ macrophages could be 
detected in the colon, interestingly, these macrophages are vitamin 
A dependent for their proper development in contrast to splenic 
CD169+ macrophages, which are LT-α-dependent and express low 
levels of F4/80 and CD11c (143, 144).
The biological functions of CD169+ macrophages are still 
imprecise. CD169+ macrophages do not mediate phagocytosis and 
are mainly involved in the regulation of the immune system rather 
than in steady-state hematopoiesis (145). However, as discussed 
below, their best described functions may be conditioned primarily 
upon their anatomic localization, and it has been proposed some 
activity in kidney pathologies and under viral infection.
CD169+ Macrophages and erythropoiesis
The BM is the main site for adult hematopoiesis where erythroid 
progenitors develop into red blood cells, a process orchestrated 
mainly by erythropoietin. Chow et al. demonstrated a new role 
for the mononuclear phagocytes as erythropoietin-complementary 
regulators. They found that CD169+ macrophages from the BM 
promoted retention of the hematopoietic stem cells (HSC) by 
acting on the Nestin+ HCS, suggesting that G-CSF signaling in 
macrophages is sufficient to promote HSC mobilization (146). 
Posteriorly, it was reported that G-CSF and depletion of CD169+ 
macrophages blocked erythropoiesis in the BM but not in the 
spleen (147). Supporting the relevant role of CD169+ macrophages 
in erythropoiesis, Falchi et al., using an in vitro erythroid stress 
model, recently reported that dexamethasone (Dex) amplified the 
number of proerytroblasts (proEry) and maintained proliferation 
in an indirect form. They showed that Dex promoted the CD169+ 
macrophage maturation and instructed to exert their erythroid 
function, thus acting as a regulator of stress erythropoiesis (148).
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Polycythemia vera (PV) and β-thalasemia (β-T) are diseases 
associated with an elevated erythropoietic activity. PV is a clonal 
stem cell disorder with the somatic JAK2V617F mutation, whereas 
β-T is an expansion of the pool of erythroid progenitors. Consistent 
with previous reports, Ramos et al. have provided experimental 
evidence suggesting that macrophage depletion in mice with the 
JAK2V617F+ mutation delayed the appearance of PV and proposed 
the JAK2V617F mutation as responsible for initiating the pathology, 
but also a stress erythropoiesis macrophage-supporting activity 
(SEMA) is required for a full manifestation of the erythroid 
phenotype in vivo (149). Together, these results are crucial for the 
identification of new therapies for hematopoiesis disorders where 
the strategies may use macrophages from BM as a new target cell.
CD169+ Macrophages and Their 
immunological Role
Invariant natural killer T cells (iNKT cells) are a subset of T 
lymphocytes that express a specific αβ T cell receptor (TCR), Vα14-
Jα18 in mice and Vα24-Jα18 in human, co-express molecules of 
NK cells (CD16, CD56), and recognize lipid antigens presented 
by CD1d molecules. CD169+ macrophages can mediate rapid and 
long-lasting interactions with iNKT cells after administration of 
lipid antigens (150). CD169+ macrophages can induce a similar 
robust activation of iNKT cells in vivo, using liposomes decorated 
with glycan (151).
Immunological tolerance is the ability the body has to dis-
tinguish between self and foreign, allowing homeostasis main-
tenance and prevention of autoimmune diseases. Two models 
propose that CD169+ macrophages are necessary to maintain 
immunological tolerance. The first model suggested that in the 
splenic MZ, apoptotic cells induce the expression of CCL22 in 
CD169+ macrophages, resulting in rapid follicular accumulation 
of Tregs and 103neg DC subset. Thus, recruited Tregs could be 
activated by apoptotic cell antigens when presented by profes-
sional antigen presenting cells or constitutively self-antigen 
presented to maintain tolerogenic stimulation (152). The second 
model proposed that CD169+ macrophages from the lymph node 
or spleen are responsible for capturing exosomes, cell-derived 
vesicles that are a potential source of self-antigens, thus suggest-
ing that CD169+ macrophages control the access of exosomes 
to lymphoid organs as a mechanism decreasing the probability 
of self-antigen responses (153). Although at date, mechanisms 
favoring generation and maintenance of immunological toler-
ance have not been totally elucidated, CD169+ macrophages can 
be considered important players.
CD169+ Macrophages in Kidney Diseases
Some kidney diseases have been associated with macrophage 
accumulation. In a model of anti-glomerular basement membrane 
(anti-GBM), adoptive transfer of macrophages showed their con-
tribution to renal injury-induced proteinuria and glomerular cell 
proliferation (154). Posteriorly, CD169+ macrophages were found 
in glomerulonephritis and there was a correlation with proteinuria 
and histologic damage, however, as CD169 marker is absent from 
blood monocytes, this work did not identify if a specific factor, 
within the glomerular microenvironment, induced the  expression 
of CD169 on macrophages or if CD169+ macrophages were 
recruited (155).
More recently, using a model of renal ischemia–reperfusion 
injury (IRI), Karasawa et  al. identified a subset of peripheral 
blood monocytes (inside CX3CR1+ subset) and kidney-resident 
macrophages, which were CD169+. However, in contrast to anti-
GBM model, the depletion of CD169+ cells resulted in progressive 
renal injury by IRI, suggesting that CD69+ cells contributed to the 
suppression or resolution of IRI (156).
CD169+ Macrophages in Their Antiviral 
Role
NK cells play a pivotal role in viral infection. Garcia et al. have 
shown that during experimental infection with recombinant 
modified vaccinia virus Ankara (MVA), viral vector used for vac-
cine purposes, NK cells accumulated in LN and became activated 
in an IFN-dependent manner. Indeed, CD169+ macrophages 
from the SCS are the main type I IFN producers and therefore 
SCS macrophages appear essential for NK cell recruitment (154). 
A second infectious viral model using vesicular stomatitis virus 
(VSV) also supported that SCS macrophage can contribute to 
antiviral immune surveillance (157, 158). With the same model 
of VSV, other group reported that CD169+ macrophages from 
the MZ were able to capture virus but allowed viral replica-
tion even in the presence of type I IFN and also overexpressed 
Usp18, a potent inhibitor of IFN signaling pathway. The lack of 
either CD169+ cells or Usp18 led to impaired adaptive immunity 
against VSV suggesting that enforced viral replication in CD169+ 
macrophages is essential for the induction of an efficient adaptive 
immune response (159).
It has been shown that increased Siglec-1 expression on human 
CD14+ monocytes in response to human immunodeficient virus 
(HIV-1) infection, correlated with viral loads that range from 
undetectable (<50 copies/ml) to unsuppressed (>800,000 RNA 
copies/ml), proposing that Siglec-1 avidly binds HIV-1 and 
facilitates virus dissemination. It is possible that sialic acids on the 
viral envelope facilitated HIV-1 infection of macrophages through 
interacting with Siglec-1 (160, 161).
TCR+ Macrophages
T cell receptor (TCR), a molecule necessary for antigen recognition 
with broad antigen specificity, forms a complex with CD3. This 
complex TCR-CD3 consists of eight chains: two from TCR that 
are mainly αβ, but occasionally γδ, plus six chains from CD3: 
δϵ, γϵ, and ζζ. For many years, it has been accepted that TCR 
expression is exclusive to T cells; however, there are no reports 
providing explicit or systematic experimental evidence that others 
leukocytes, different from the T cell lineage are unable to express 
TCR. Puellmann et al. reported experimental data changing this 
dogma (162).
In 2006, it was reported that 5–8% of neutrophils in the 
circulation express TCR-αβ complex, comprising CD3 and 
individual-specific TCR Vαβ repertoires, the engagement of the 
CD3-dependent TCR signal in neutrophils inhibited apoptosis and 
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increased IL-8 expression (162, 163). In addition, other  cellular 
subsets from polymorphonuclear group were also shown to express 
TCR. Interestingly, there are eosinophil subsets that are TCRγδ+ 
and TCRαβ−, when these cells were activated by CD3 (unspecific 
stimulus) led to ROS production, eosinophil peroxidase (EPO), 
eosinophil-derived neurotoxin (EDN), and cytokine release. 
However, when eosinophils were activated by mycobacterial 
ligands (specific stimulus), which are efficient to activate T cells 
TCRγδ+, they produced ROS and EPO but released cytokines 
were not documented. Finally, this subpopulation also had an 
anti-tumor cytotoxicity activity, thus eosinophils TCRγδ+ are 
relevant to the immune defense (164).
Regarding macrophage cellular subpopulations, several 
publications have reported the presence of both humans and 
murine TCR+ macrophages. The TCR-αβ was described to be 
expressed by peripheral blood monocytes and in vitro by activated 
monocyte-derived macrophages. Using an in vitro model, Beham 
et  al. showed that TCRβ locus rearrangement and expression 
of Vβ repertoires in the myeloid lineage occurred during the 
early phase of macrophage differentiation. TCR+ macrophages 
have the ability to release CCL2 and possess high-phagocytosis 
capacity. These cells express molecules such as ZAP70, LAT, Fyn, 
and Lck, necessary for TCR signaling on lymphocytes; however, 
their concentration was different when macrophages received 
IL-4 or IFN-γ stimuli that determine different macrophages’ 
polarization. Interestingly, during M. tuberculosis infection, which 
derived pathology involves granuloma formation, macrophages 
at the inner epithelioid cell zone of caseous granulomas are TCR+ 
macrophages. Neutralization of TNF (cytokine necessary for host 
resistance to M. tuberculosis) in patients with lung tuberculosis, 
suppressed the expression of the CD3 ζ-subunit on TCR+ mac-
rophages, becoming unstable to form the complex TCR-CD3, 
and the number of TCR+ macrophages decreased. Anti-TNF 
treatment is also associated with granuloma disorganization and 
reduced CCL2 expression, thus suggesting that TNF is a regulator 
of TCRαβ expression on macrophages (165).
Recently, Fuchs et  al. reported that in both murine and 
human lesions of atherosclerosis, there is accumulation of 
TCRαβ+ macrophages. Using an in vitro cholesterol import and 
export model, this group proposed that high-density lipoprotein 
(HDL)-mediated cholesterol efflux induced downregulation 
of TCRβ within 24 h, but after 72 h, low-density lipoprotein 
FiGURe 3 | Molecules associated with macrophage subsets. M1 
macrophages, also called classically activated, respond to stimuli such as LPS, 
IFN-γ, and are important producers of pro-inflammatory cytokines. M2 
macrophages, also called alternatively active respond to stimuli such as IL-4 or 
IL-13, are producer of anti-inflammatory cytokines. Tumor-associated 
macrophages (TAM) respond to self-tumor microenvironment and secrete 
cytokines such as TGF-β or IL-10. CD169+ macrophages are involved in 
immune tolerance and erythropoiesis. TCR+ macrophages are a new 
subpopulation of macrophages that release chemokine CCL2 and play a role in 
inflammatory and infectious diseases. Names in black = usually described. 
Names in white = under specific circumstances can be present in different 
concentrations.
May 2015 | Volume 6 | Article 26311
Chávez-Galán et al. Macrophage subsets and pathologies
Frontiers in Immunology | www.frontiersin.org
(LDL) ingestion by macrophages-induced changes of TCRβ 
chains in human carotid artery lesion. Thus, cholesterol 
import/export was identified as a potent in  vitro modulator 
of macrophages-TCRβ repertoire expression and the presence 
of TCRαβ+ macrophages was suggested as a new signature 
of atherosclerosis representing a novel molecular target for 
diagnostic and treatment of diseases where cholesterol plays 
a main role in physiopathology (166).
A recent report has shown that monocytes/macrophages from 
both humans and mice, constitutively express a second type of 
combinatorial receptor based on γδ variable chains, however, 
after a bacterial exposure, a distinct TCR Vδ repertoire is induced 
suggesting that TCRγδ represents a flexible host defense system 
that responds to bacterial challenge (167).
In conclusion, although the numbers of reports are still 
limited, there are evidences suggesting that the expression of 
TCR on cellular surface of non-lymphoid cells, including neu-
trophils, eosinophils, and monocytes/macrophages, specially, 
both TCRαβ+ and TCRγδ+ macrophages are implicated in 
inflammatory and infectious diseases.
Perspectives
For several decades, great progress has been accomplished 
in the definition of lymphocyte populations by refining their 
phenotypic profile and characterizing their distinct functions. 
At present, the knowledge of macrophage subpopulations 
is still growing. Initially divided according to their ability to 
release pro-inflammatory or anti-inflammatory cytokines as a 
paradigm to mimic Th1 and Th2 subsets, these macrophages 
were designed as M1 and M2 macrophages. Nowadays, besides 
M1 and M2 macrophages, other different subpopulations, which 
have been described, such as TAM, CD169+, or TCR+, that are 
differently located and possess their own characteristics and 
functionalities. The importance of macrophages on the immune 
response is indubitable; they are necessary in controlling infec-
tious processes, but their presence is also necessary to maintain 
homeostasis under sterile injury. In the Figure 3, we summarize 
some of the main features of macrophage subpopulations dis-
cussed in this review.
Many questions remain unsolved in this field, and more efforts 
are needed to establish origin, specific markers, conditions of 
appropriate stimuli for macrophage polarization, and steps of 
the differentiation process leading to different subpopulation of 
macrophages. It is still not clear the relationship between human 
macrophages versus animal model system and this knowledge is 
important to advance in the design of new therapeutic strategies 
supplementing those established in different pathological condi-
tions such as cancer, infectious disease, obesity, and asthma. 
Moreover, preclinical and clinical observations demonstrate an 
association between macrophage number/type and prognosis 
in variety malignancies.
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